📊 CLYM Key Takeaways
Investment Thesis
Climb Bio is a pre-revenue biopharmaceutical company with significant cash burn (-$54.4M operating cash flow) and no meaningful revenue generation, characteristic of early-stage drug development. While the company maintains adequate liquidity ($35.7M cash) and minimal debt, the combination of substantial operating losses (-$67.9M), negative returns on equity (-37.3%) and assets (-35.7%), and accelerating cash consumption presents material near-term survival risk without successful clinical advancement or financing.
CLYM Strengths
- Strong liquidity position with 15.16x current ratio and $35.7M cash reserves
- No long-term debt, minimizing financial obligations and leverage risk
- Improved diluted EPS trend (+42.5% YoY) suggesting share count management
CLYM Risks
- Pre-revenue stage with no commercial products generating cash flow
- Severe ongoing operating losses (-$67.9M) with negative free cash flow (-$54.5M)
- Estimated 7-8 month cash runway at current burn rate without additional capital raises
- Negative ROE (-37.3%) and ROA (-35.7%) indicate value destruction
- 7 Form 4 filings in 90 days may indicate insider concern or volatility
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway extension
- Clinical trial advancement milestones and regulatory pathway progress
- Capital raise announcements and dilution impact on shareholder value
- Operating expense trends and development spending efficiency
CLYM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 15.16x current ratio provides a solid financial cushion.
CLYM Profitability Ratios
CLYM vs Healthcare Sector
How Climb Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLYM Balance Sheet & Liquidity
CLYM 5-Year Financial Trend
5-Year Trend Summary: Climb Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.53 indicates the company is currently unprofitable.
CLYM Growth Metrics (YoY)
CLYM Capital Allocation
CLYM SEC Filings
Access official SEC EDGAR filings for Climb Bio, Inc. (CIK: 0001768446)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLYM
What is the AI rating for CLYM?
Climb Bio, Inc. (CLYM) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLYM's key strengths?
Strong liquidity position with 15.16x current ratio and $35.7M cash reserves. No long-term debt, minimizing financial obligations and leverage risk.
What are the risks of investing in CLYM?
Pre-revenue stage with no commercial products generating cash flow. Severe ongoing operating losses (-$67.9M) with negative free cash flow (-$54.5M).
What is CLYM's revenue and growth?
Climb Bio, Inc. reported revenue of N/A.
Does CLYM pay dividends?
Climb Bio, Inc. does not currently pay dividends.
Where can I find CLYM SEC filings?
Official SEC filings for Climb Bio, Inc. (CIK: 0001768446) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLYM's EPS?
Climb Bio, Inc. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.